Compare COEP & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COEP | PCM |
|---|---|---|
| Founded | 2017 | 1993 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.2M | 82.0M |
| IPO Year | N/A | N/A |
| Metric | COEP | PCM |
|---|---|---|
| Price | $16.40 | $5.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 92.3K | 44.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.68% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.80 | $5.52 |
| 52 Week High | $21.41 | $6.76 |
| Indicator | COEP | PCM |
|---|---|---|
| Relative Strength Index (RSI) | 72.18 | 43.55 |
| Support Level | $13.77 | $5.60 |
| Resistance Level | $19.19 | $6.15 |
| Average True Range (ATR) | 1.15 | 0.06 |
| MACD | 0.47 | -0.00 |
| Stochastic Oscillator | 87.62 | 26.67 |
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.